PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL
Peter Dreger(Heidelberg University), Mehdi Hamadani(Medical College of Wisconsin), Carlos Litovich(Medical College of Wisconsin), Javier Bolaños‐Meade(Johns Hopkins University), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Silvia Montoto(Queen Mary University of London), Luca Castagna(Humanitas University), Didier Blaise(Institut Paoli-Calmettes), Fabio Ciceri(Vita-Salute San Raffaele University), Stephen Robinson(Intel (United States)), Alex F. Herrera(City of Hope), Johanna Tischer(LMU Klinikum), Mary Eapen(Medical College of Wisconsin), Mahasweta Gooptu(Harvard University), Monzr M. Al Malki(City of Hope), Paolo Corradini(Gruppo di Ricerca Geriatrica), Christoph Schmid(University Hospital Augsburg), José L. Díez‐Martín(Universidad Complutense de Madrid), Hervé Finel, Zafer Gülbaş, Ephraim J. Fuchs(Johns Hopkins University), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Alida Dominietto(Ospedale Policlinico San Martino), Kwang Woo Ahn(Medical College of Wisconsin), Stefan O. Ciurea(University of California, Irvine), Ariane Boumendil(Inserm)
Cited by 115
Related Papers
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k